Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Depreciation & Amortization (CF): 2015-2023

Historic Depreciation & Amortization (CF) for Spyre Therapeutics (SYRE) over the last 8 years, with Jun 2023 value amounting to $360,000.

  • Spyre Therapeutics' Depreciation & Amortization (CF) fell 4.76% to $360,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $1.5 million, marking a year-over-year decrease of 4.61%. This contributed to the annual value of $744,000 for FY2023, which is 52.52% down from last year.
  • Per Spyre Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $360,000 for Q2 2023, which was down 6.25% from $384,000 recorded in Q1 2023.
  • Over the past 5 years, Spyre Therapeutics' Depreciation & Amortization (CF) peaked at $412,000 during Q3 2021, and registered a low of $100,000 during Q1 2019.
  • Its 3-year average for Depreciation & Amortization (CF) is $388,700, with a median of $391,500 in 2021.
  • Per our database at Business Quant, Spyre Therapeutics' Depreciation & Amortization (CF) spiked by 248.11% in 2020 and then dropped by 6.33% in 2022.
  • Quarterly analysis of 5 years shows Spyre Therapeutics' Depreciation & Amortization (CF) stood at $106,000 in 2019, then surged by 248.11% to $369,000 in 2020, then increased by 11.38% to $411,000 in 2021, then declined by 6.33% to $385,000 in 2022, then dropped by 4.76% to $360,000 in 2023.
  • Its last three reported values are $360,000 in Q2 2023, $384,000 for Q1 2023, and $385,000 during Q4 2022.